Related Experiment Video
Updated: Aug 15, 2026

Rapid Generation of Amyloid from Native Proteins In vitro
Published on: December 5, 2013
The pathogenesis of beta(2)-microglobulin-induced bone lesions in dialysis-related amyloidosis
M Tran1, G W Rutecki, S M Sprague
1Department of Medicine, Division of Nephrology, Evanston Northwestern Healthcare, Evanston, Illinois 60201, USA.
Abstract:
Dialysis-related amyloidosis (DRA), also referred to as beta(2)-microglobulin amyloidosis (A beta(2)M), is an important cause of morbidity in patients with chronic renal failure and in those who are on dialysis. Although DRA deposits from affected joints have been characterized as a unique amyloid fibril protein, beta(2)M, less is known about the pathologic role of beta(2)M as a mediator of bone and joint disease. Potential mechanisms for beta(2)M pathologic interaction in bone include bone growth factors, cytokines, and advanced glycation end products (AGEs). It appears that DRA is the result of a complex interaction between bone resorption and surrounding tissue destruction culminating in beta(2)M deposition and amyloid formation. More work is required to elucidate the relationship between beta(2)M accumulation and progressive tissue destruction.
Insights
Dialysis-related amyloidosis (DRA), caused by beta(2)-microglobulin (Aβ2M) deposition, leads to significant morbidity in dialysis patients. Further research is needed to understand the complex mechanisms linking Aβ2M accumulation to bone and joint destruction.
Area of Science:
- Nephrology
- Rheumatology
- Biochemistry
Background:
- Dialysis-related amyloidosis (DRA), or beta(2)-microglobulin amyloidosis (Aβ2M), is a major complication in chronic renal failure patients undergoing dialysis.
- While the amyloid fibril protein in DRA is identified as beta(2)-microglobulin (β2M), its specific role in bone and joint pathology remains unclear.
Purpose of the Study:
- To explore the pathological mechanisms by which β2M contributes to bone and joint disease in the context of DRA.
- To investigate potential interactions between β2M and factors like growth factors, cytokines, and advanced glycation end products (AGEs) in bone.
Main Methods:
- Characterization of DRA deposits in affected joints.
- Review of potential molecular mechanisms involved in β2M's interaction with bone tissue.
Main Results:
- DRA is characterized by the deposition of β2M amyloid fibrils.
- Potential pathways for β2M's pathological role in bone involve growth factors, cytokines, and AGEs.
Conclusions:
- DRA results from a complex interplay of bone resorption and tissue damage, leading to β2M deposition and amyloid formation.
- Further investigation is required to fully elucidate the relationship between β2M accumulation and progressive tissue destruction in DRA.
More Related Videos
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Diabetic Nephropathy

